ALK and non-small cell lung carcinoma: We evaluated the treatment and outcomes of 40 ALK-rearranged NSCLC patients treated in 5 years in a single Italian Institution; most of the patients have been treated into clinical trials or in expanded access programs, because in Italy crizotinib has been the only ALK inhibitor available up to now.